As tensions persist over the cost of insulin, two U.S. senators want three of the nation’s largest health insurers to provide a raft of data about pricing, rebates, and plan coverage.

In each case, Aetna (AET), Anthem (ANTM), and UnitedHealthcare (UNH) are being asked to fork over information about the effect that rebates have on their insulin spending, how rebates from drug makers may reduce expenses for beneficiaries, and the relationship between insulin pricing and what patients pay at pharmacies, among other things.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy